Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species-Reference-Cited by-同舟云学术

Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species

Published:2020-05-26 Issue:13 Volume:63 Page:7226-7242
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Yang Wu¹^ORCID,Wang Yufeng¹,Lai Amy¹,Clark Charles G.¹,Corte James R.¹^ORCID,Fang Tianan¹,Gilligan Paul J.¹,Jeon Yoon¹,Pabbisetty Kumar B.¹^ORCID,Rampulla Richard A.¹,Mathur Arvind¹,Kaspady Mahammed²,Neithnadka Premsai Rai²,Arumugam Arunachalam²,Raju Sivashankaran²,Rossi Karen A.¹,Myers Joseph E.¹,Sheriff Steven¹,Lou Zhen¹,Zheng Joanna J.¹,Chacko Silvi A.¹,Bozarth Jeffrey M.¹,Wu Yiming¹,Crain Earl J.¹,Wong Pancras C.¹,Seiffert Dietmar A.¹,Luettgen Joseph M.¹,Lam Patrick Y. S.¹,Wexler Ruth R.¹,Ewing William R.¹^ORCID

Affiliation:

1. Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08540, United States

2. Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot nos. 2 and 3, Bommasandra−Jigani Road, Bangalore 560100, India

Funder

Bristol-Myers Squibb

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00464

Reference31 articles.

1. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017

2. Overview of the New Oral Anticoagulants

3. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

4. Factor XIa Inhibitors as New Anticoagulants

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Macrocyclic-based strategy in drug design: From lab to the clinic;European Journal of Medicinal Chemistry;2024-11

2. Design, synthesis and biological evaluation of 6-chloro-quinolin-2-one derivatives as novel FXIa inhibitors;Bioorganic & Medicinal Chemistry Letters;2024-02

3. A comprehensive review of discovery and development of drugs discovered from 2020–2022;Saudi Pharmaceutical Journal;2024-01

4. Molecular dynamics simulation of the inhibition mechanism of factor XIa by Milvexian-like macrocyclic inhibitors;Computational and Theoretical Chemistry;2023-07

5. Stereoselective synthesis of tetrahydropyrimidin-2(1H)-ones (minireview);Chemistry of Heterocyclic Compounds;2023-05